Bsolulymfooma

Burkitt's lymphoma, also known as Burkitt's tumor, is a type of non-Hodgkin lymphoma that is characterized by the rapid growth of malignant B cells. It was first described by British pathologist Denis Burkitt in 1958. The disease is most commonly found in children and young adults in Africa, particularly in regions with high rates of malaria and Epstein-Barr virus (EBV) infection. In these regions, Burkitt's lymphoma is often associated with EBV and is known as endemic Burkitt's lymphoma. In contrast, Burkitt's lymphoma in other parts of the world, including the United States, is sporadic and not associated with EBV. It is often referred to as non-endemic Burkitt's lymphoma.

Burkitt's lymphoma typically affects the jaw, abdomen, or head and neck region. The disease is aggressive and can spread rapidly to other parts of the body, including the lungs, liver, and bone marrow. The prognosis for Burkitt's lymphoma varies depending on the type and stage of the disease. Endemic Burkitt's lymphoma has a high cure rate, with survival rates of over 90% in some cases. Non-endemic Burkitt's lymphoma, however, has a lower cure rate, with survival rates ranging from 50% to 70%.

Treatment for Burkitt's lymphoma typically involves a combination of chemotherapy, radiation therapy, and surgery. In some cases, stem cell transplantation may also be used. The goal of treatment is to shrink the tumor, eliminate cancer cells, and prevent the disease from spreading. Regular follow-up care is important to monitor for any signs of recurrence.